Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maha A Al-Ammari"'
Autor:
Abdulrahman M Al-Turaiki, Maha A Al-Ammari, Shmeylan A Al-Harbi, Nabil S Khalidi, Abdulmalik M Alkatheri, Tariq M Aldebasi, Salah M AbuRuz, Abdulkareem M Albekairy
Publikováno v:
Annals of Thoracic Medicine, Vol 11, Iss 2, Pp 146-150 (2016)
Aims: No previous reports on the utilization of CHADS2, CHA2DS2-VASc, and HAS-BLED scores in atrial fibrillation (AF) patients in Saudi Arabia have been identified in the literature. The main objectives of this study were to assess and compare the di
Externí odkaz:
https://doaj.org/article/427ba51f90cd4d7598654b36235c945b
Autor:
Mohammed AlBalwi, Nada S Almakhlafi, Mohammed Aldrees, Maha A. Al Ammari, Bader Almuzzaini, Jahad Alghamdi, Khizra Sultana, Ibrahim B Alabdulkareem
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Scientific Reports
Scientific Reports
Warfarin is a frequently prescribed oral anticoagulant with a narrow therapeutic index, requiring careful dosing and monitoring. However, patients respond with significant inter-individual variability in terms of the dose and responsiveness of warfar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da8e4698cde356226e74ff67856d3c9f
http://link.springer.com/article/10.1038/s41598-020-68519-9
http://link.springer.com/article/10.1038/s41598-020-68519-9
Autor:
Maha A Al Ammari
Publikováno v:
Archives of Asthma, Allergy and Immunology. 3:003-009
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c47a4f301a0235865f768951ba72e63a
https://doi.org/10.29328/journal.aaai.1001016
https://doi.org/10.29328/journal.aaai.1001016
Publikováno v:
Saudi Medical Journal
Saudi Medical Journal, Vol 40, Iss 11, Pp 1116-1122 (2019)
Saudi Medical Journal, Vol 40, Iss 11, Pp 1116-1122 (2019)
Objectives : To assess the effectiveness and safety profile of the new disease modifying drugs (fingolimod, teriflunomide, and dimethyl fumarate) at a local hospital in Riyadh, Saudi Arabia. Methods : This is a retrospective cohort, where institution
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce84e19bd115fc8a8498a91922d444ba
http://europepmc.org/articles/PMC6901776
http://europepmc.org/articles/PMC6901776
Autor:
Maha A. Al Ammari, Zohour Bootah, Shmeylan Al Harbi, Nouf Al Otaib, Salah AbuRuz, Tariq Aldebasi, Abdulmalik M. Alkatheri, Abdulkareem M. Albekairy
Publikováno v:
Annals of Thoracic Medicine
Annals of Thoracic Medicine, Vol 12, Iss 3, Pp 199-203 (2017)
Annals of Thoracic Medicine, Vol 12, Iss 3, Pp 199-203 (2017)
Background: Venous thromboembolism (VTE) can be encountered by 60% of hospitalized patients. Anticoagulants have been recommended to reduce the risk of VTE in patients with risk factors. However, no specific dosing recommendations for obese patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ad285d3d68fddc3bfc17427bc50b89e
http://europepmc.org/articles/PMC5541968
http://europepmc.org/articles/PMC5541968
Autor:
Nada Al Maklafi, Maha A. Al Ammari, Abin Thomas, Shatha M. Al Halwan, Omar A Alzuwayed, Dalal A Al-Abdulkarim
Publikováno v:
Saudi Journal of Kidney Diseases and Transplantation, Vol 31, Iss 5, Pp 1057-1061 (2020)
Colistin-induced nephrotoxicity is a well-known major adverse event, which may occur within seven days [early acute kidney injury (AKI)] with a high mortality rate of 70% or after seven days (late AKI). The main objective of this retrospective study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93cd845168658bcb5c14ec885669d0e5
https://doi.org/10.4103/1319-2442.301171
https://doi.org/10.4103/1319-2442.301171
Autor:
Nouf Al Otaib, Zohour Bootah, Maha A Al Ammari, Tariq M Aldebasi, Abdulmalik M Alkatheri, Shmeylan A Al Harbi, Salah M AbuRuz, Abdulkareem M AlBekairy
Publikováno v:
Annals of Thoracic Medicine, Vol 12, Iss 3, Pp 199-203 (2017)
Background: Venous thromboembolism (VTE) can be encountered by 60% of hospitalized patients. Anticoagulants have been recommended to reduce the risk of VTE in patients with risk factors. However, no specific dosing recommendations for obese patients
Externí odkaz:
https://doaj.org/article/08efcd7fa806421d8dcae1b13e5a61d2